Patient portrayal

Finding treatment through
biomarker testing

Biomarker testing is an important part of understanding your unique advanced NSCLC diagnosis. It is used in the advanced stages of NSCLC and involves testing tumor tissue for mutations or abnormalities in the DNA and levels of specific proteins in, or on the surface of, the tumor. Biomarkers tell your doctor that a mutation or an abnormality may be present and may lead to a better understanding of which treatment to use and how you may respond to treatment.

What are the types of biomarkers?

There are many different biomarker tests that may help you and your doctor decide the most appropriate treatment options to help treat your advanced NSCLC. Your doctor may test you for more than one biomarker. Below are some of the most common types of biomarkers.

Select one of the biomarkers below to get more information.

Anaplastic lymphoma kinase (A-nuh-PLAS-tik lim-FOH-muh KY-nays) (ALK) The ALK gene causes cells to grow and divide more rapidly. ALK mutations may cause tumors to grow out of control.
LIBTAYO is not an appropriate therapy for patients who test positive for ALK mutations.
B-Raf proto-oncogene, serine/threonine kinase (b-raf prow-tuh-aang-kow-jeen, sr-een/
three-uh-neen KY-nays) (BRAF)
The BRAF gene makes a protein that is involved in sending signals in cells. BRAF mutations
may cause cancer cells to grow and spread in the body more rapidly.
Epidermal growth factor receptor (eh-pih-DER-mul grothe FAK-ter reh-SEP-ter) (EGFR) The EGFR protein is involved in cell growth and cell survival. EGFR mutations may cause cancer cells to grow and spread in the body more rapidly. LIBTAYO is not an appropriate therapy for patients who test positive for EGFR mutations.
Neurotrophic tyrosine receptor kinase (NOOR-oh-TROH-fik TY-ruh-seen reh-SEP-ter KY-nays) (NTRK) The NTRK gene family produces proteins that control cell growth and survival. NTRK mutations can
lead to the formation of abnormal proteins, which may cause uncontrolled growth of cancer cells.
Programmed death ligand 1 (prow-gramd deth li-gand wuhn) (PD-L1) PD-L1 is a protein that acts as a kind of “brake” to keep the body’s immune responses under
control. PD-L1 binds to another protein found on T cells called programmed death receptor-1
(PD-1). This binding keeps T cells from killing normal cells and cancer cells that contain PD-L1.
LIBTAYO is not appropriate for patients with PD-L1 level less than 50%.
ROS proto-oncogene 1, receptor tyrosine kinase (ros prow-tuh-aang-kow-jeen wuhn, reh-SEP-ter TY-ruh-seen KY-nays) (ROS1) The ROS1 protein is involved in sending signals in cells and in cell growth. ROS1 mutations may cause cancer
cells to grow. LIBTAYO is not an appropriate therapy for patients who test positive for ROS1 mutations.

Immunotherapy biomarkers

Some treatment options depend on the presence or absence of biomarkers. Biomarker testing is used to determine if you may have a mutation or an abnormality that is treatable or to measure your programmed death ligand 1 (PD-L1) level. The results of these tests help determine whether any of the FDA-approved targeted therapies or immunotherapies may be right for your treatment plan. PD-L1 is currently used to help decide whether your advanced NSCLC may respond to treatment with immunotherapy.

PD-L1 is a protein that acts as a kind of “brake” to keep the body’s immune responses under control. PD-L1 binds to another protein found on T cells called programmed death receptor-1 (PD-1). This binding keeps T cells from killing normal cells and cancer cells that contain PD-L1.

If you test negative for abnormal EGFR, ALK, or ROS1 genes and have a high PD-L1 level (greater than or equal to 50%), LIBTAYO may be an appropriate treatment option for your advanced NSCLC.

Discover if LIBTAYO may be a treatment option for you.

Learn more about LIBTAYO